Your browser doesn't support javascript.
loading
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto, Emilio; Ferrero, Simone; Bommier, Côme; Drandi, Daniela; Ferrante, Martina; Bouabdallah, Krimo; Carras, Sylvain; Gini, Guido; Camus, Vincent; Mancuso, Salvatrice; Marcheselli, Luigi; Ferrari, Angela; Merli, Michele; Tessoulin, Benoit; Stelitano, Caterina; Beldjord, Kheira; Roti, Giovanni; Jardin, Fabrice; Castagnari, Barbara; Palombi, Francesca; Baseggio, Lucile; Traverse-Glehen, Alexandra; Tripodo, Claudio; Liberati, Anna Marina; Parolini, Margherita; Usai, Sara; Patti, Caterina; Federico, Massimo; Musso, Maurizio; Ladetto, Marco; Zucca, Emanuele; Thieblemont, Catherine.
Afiliação
  • Iannitto E; La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palemo, Italy; Tumor Immunology Unit Department of Health Sciences University of Palermo School of Medicine. Istituto di Patologia Generale, Palermo.
  • Ferrero S; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
  • Bommier C; Universitè Paris Citè; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
  • Drandi D; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
  • Ferrante M; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino.
  • Bouabdallah K; CHU de Bordeaux - Hôpital Haut Lèvêque and Centre François Magendie, Service d'Hématologie Clinique et Thérapie Cellulaire, Pessac.
  • Carras S; Univ. Grenoble Alpes. Institute For Advanced Biosciences (INSERM U1209, CNRS UMR 5309). University Hospital, Molecular Biology and Hematology departments, Grenoble.
  • Gini G; Ematologia AOU delle Marche, Ancona.
  • Camus V; Department of Hematology, Centre Henri Becquerel, Rouen.
  • Mancuso S; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), Hematology Unit, University of Palermo.
  • Marcheselli L; Fondazione Italiana Linfomi ETS, Modena.
  • Ferrari A; Azienda Unità Sanitaria Locale-IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia.
  • Merli M; Hematology, Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi, Varese.
  • Tessoulin B; Nantes University Hospital and CRC2 NA, Nantes.
  • Stelitano C; UO Ematologia AO Bianchi-Melacrino-Morelli, Reggio Calabria.
  • Beldjord K; Universitè Paris Citè.
  • Roti G; Dipartimento di Medicina e Chirurgia, Università di Parma, AOU di Parma.
  • Jardin F; Ematologia AOU delle Marche, Ancona.
  • Castagnari B; Department of Hematology, Ravenna hospital, Ravenna.
  • Palombi F; Hematology Unit, IRCCS Regina Elena National Cancer Institute, Roma.
  • Baseggio L; Laboratoire d'Hèmatologie Biologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon.
  • Traverse-Glehen A; Service d'Anatomie Pathologique, Groupement Hospitalier Lyon-Sud/Hospices Civils de Lyon.
  • Tripodo C; Tumor Immunology Unit Department of Health Sciences University of Palermo School of Medicine. Istituto di Patologia Generale, Palermo.
  • Liberati AM; Oncohematology Unit, University of Perugia, Azienda Ospedaliera S.Maria, Terni.
  • Parolini M; Ematologia Istituto Romagnolo Per Lo studio dei Tumori Dino Amadori, Meldola.
  • Usai S; Ospedale Oncologico A. Businco, Cagliari.
  • Patti C; U.O.C. di Oncoematologia Ospedali Riuniti Villa Sofia - Cervello, Palermo.
  • Federico M; CHIMOMO dept. University of Modena and Reggio Emilia.
  • Musso M; La Maddalena Department of Oncology, Onco-Hematology and Bone Marrow Transplantation Unit, Palemo.
  • Ladetto M; University of Eastern Piedmont Amedeo Avogadro S.S. Antonio and Biagio and Cesaro Arrigo Hospital, Alessandria.
  • Zucca E; IOSI, Oncology Institute of Southern Switzerland and IOR: Institute of Oncology Research IELSG International Extranodal Lymphoma Study, Bellinzona, Switzerland.
  • Thieblemont C; Universitè Paris Citè; AP-HP, Hôpital Saint-Louis, Hemato-oncologie, Paris.
Haematologica ; 109(7): 2297-2302, 2024 07 01.
Article em En | MEDLINE | ID: mdl-38497158
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esplênicas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasia Residual / Linfoma de Zona Marginal Tipo Células B / Cloridrato de Bendamustina / Rituximab Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esplênicas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasia Residual / Linfoma de Zona Marginal Tipo Células B / Cloridrato de Bendamustina / Rituximab Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article